Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer
Standard
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. / Hannemann, Juliane; Oosterkamp, Hendrika M; Bosch, Cathy A J; Velds, Arno; Wessels, Lodewyk F A; Loo, Claudette; Rutgers, Emiel J; Rodenhuis, Sjoerd; van de Vijver, Marc J.
In: J CLIN ONCOL, Vol. 23, No. 15, 20.05.2005, p. 3331-42.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer
AU - Hannemann, Juliane
AU - Oosterkamp, Hendrika M
AU - Bosch, Cathy A J
AU - Velds, Arno
AU - Wessels, Lodewyk F A
AU - Loo, Claudette
AU - Rutgers, Emiel J
AU - Rodenhuis, Sjoerd
AU - van de Vijver, Marc J
PY - 2005/5/20
Y1 - 2005/5/20
N2 - PURPOSE: At present, clinically useful markers predicting response of primary breast carcinomas to either doxorubicin-cyclophosphamide (AC) or doxorubicin-docetaxel (AD) are lacking. We investigated whether gene expression profiles of the primary tumor could be used to predict treatment response to either of those chemotherapy regimens.PATIENTS AND METHODS: Within a single-institution, randomized, phase II trial, patients with locally advanced breast cancer received six courses of either AC (n = 24) or AD (n = 24) neoadjuvant chemotherapy. Gene expression profiles were generated from core-needle biopsies obtained before treatment and correlated with the response of the primary tumor to the chemotherapy administered. Additionally, pretreatment gene expression profiles were compared with those in tumors remaining after chemotherapy.RESULTS: Ten (20%) of 48 patients showed a (near) pathologic complete remission of the primary tumor after treatment. No gene expression pattern correlating with response could be identified for all patients or for the AC or AD groups separately. The comparison of the pretreatment biopsy and the tumor excised after chemotherapy revealed differences in gene expression in tumors that showed a partial remission but not in tumors that did not respond to chemotherapy.CONCLUSION: No gene expression profile predicting the response of primary breast carcinomas to AC- or AD-based neoadjuvant chemotherapy could be detected in this interim analysis. More subtle differences in gene expression are likely to be present but can only be reliably identified by studying a larger group of patients. Response of a breast tumor to neoadjuvant chemotherapy results in alterations in gene expression.
AB - PURPOSE: At present, clinically useful markers predicting response of primary breast carcinomas to either doxorubicin-cyclophosphamide (AC) or doxorubicin-docetaxel (AD) are lacking. We investigated whether gene expression profiles of the primary tumor could be used to predict treatment response to either of those chemotherapy regimens.PATIENTS AND METHODS: Within a single-institution, randomized, phase II trial, patients with locally advanced breast cancer received six courses of either AC (n = 24) or AD (n = 24) neoadjuvant chemotherapy. Gene expression profiles were generated from core-needle biopsies obtained before treatment and correlated with the response of the primary tumor to the chemotherapy administered. Additionally, pretreatment gene expression profiles were compared with those in tumors remaining after chemotherapy.RESULTS: Ten (20%) of 48 patients showed a (near) pathologic complete remission of the primary tumor after treatment. No gene expression pattern correlating with response could be identified for all patients or for the AC or AD groups separately. The comparison of the pretreatment biopsy and the tumor excised after chemotherapy revealed differences in gene expression in tumors that showed a partial remission but not in tumors that did not respond to chemotherapy.CONCLUSION: No gene expression profile predicting the response of primary breast carcinomas to AC- or AD-based neoadjuvant chemotherapy could be detected in this interim analysis. More subtle differences in gene expression are likely to be present but can only be reliably identified by studying a larger group of patients. Response of a breast tumor to neoadjuvant chemotherapy results in alterations in gene expression.
KW - Adult
KW - Aged
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Breast Neoplasms/drug therapy
KW - Cyclophosphamide/therapeutic use
KW - Docetaxel
KW - Doxorubicin/therapeutic use
KW - Female
KW - Gene Expression Profiling
KW - Gene Expression Regulation, Neoplastic
KW - Genetic Markers/genetics
KW - Humans
KW - Middle Aged
KW - Multigene Family
KW - Neoadjuvant Therapy
KW - Neoplasm Invasiveness/pathology
KW - Neoplasm Staging
KW - Prognosis
KW - RNA, Neoplasm/genetics
KW - Risk Assessment
KW - Sensitivity and Specificity
KW - Survival Analysis
KW - Taxoids/therapeutic use
KW - Treatment Outcome
U2 - 10.1200/JCO.2005.09.077
DO - 10.1200/JCO.2005.09.077
M3 - SCORING: Journal article
C2 - 15908647
VL - 23
SP - 3331
EP - 3342
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 15
ER -